Opus Genetics Q3 revenue falls and misses analyst estimates
IRD•Opus Genetics reported Q3 revenue of $1.14 million, below the $1.96 million analyst consensus, and a net loss of $46.50 million. The company expects its cash runway to fund operations into 2029.
1. Revenue and loss
Q3 revenue, mainly from research and development service reimbursements under the Viatris collaboration, fell short of analyst expectations. The net loss widened to $46.50 million, with higher R&D costs, lower revenue and fair value changes contributing.
2. Company outlook
Opus Genetics expects its cash runway to fund operations into 2029. It expects topline data from OPGx-BEST1 Cohort 2 in Q1 2027 and plans to begin dosing in the OPGx-LCA5 Phase 3 trial in Q4 2026.
